T2 mapping in Duchenne muscular dystrophy: Distribution of disease activity and correlation with clinical assessments

Radiology

Volumn 255, Issue 3, 2010, Pages 899-908

  Kim, Hee Kyung ^a   Laor, Tal ^a   Horn, Paul S ^b   Racadio, Judy M ^a   Wong, Brenda ^a   Dardzinski, Bernard J ^a,c  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CREATINE KINASE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE SEVERITY; DUCHENNE MUSCULAR DYSTROPHY; GLUTEUS MAXIMUS MUSCLE; GOWER SCORE; HUMAN; LEG MUSCLE; MALE; MUSCULAR DYSTROPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM;

ADIPOSE TISSUE; ADOLESCENT; ANALYSIS OF VARIANCE; BIOPSY; BUTTOCKS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LOGISTIC MODELS; MAGNETIC RESONANCE IMAGING; MALE; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; PELVIS; PROSPECTIVE STUDIES; THIGH;

EID: 77952684112     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.10091547     Document Type: Article

References (40)

1. Danieli GA, Mostacciuolo ML, Bonfante A, Angelini C. Duchenne muscular dystrophy: a population study. Hum Genet 1977;35(2):225-231.
2. Monaco AP. Molecular human genetics and the Duchenne/Becker muscular dystrophy gene. Mol Cell Biol Hum Dis Ser 1993;3: 1-11.
3. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci U S A 1993;90(8):3710-3714.
4. McDouall RM, Dunn MJ, Dubowitz V. Nature of the mononuclear infiltrate and the mechanism of muscle damage in juvenile dermatomyositis and Duchenne muscular dystrophy. J Neurol Sci 1990;99(2-3):199-217. (Pubitemid 20387378)
5. Strober JB. Therapeutics in Duchenne muscular dystrophy. NeuroRx 2006;3(2): 225-234.
6. Angelini C. The role of corticosteroids in muscular dystrophy:a critical appraisal. Muscle Nerve 2007;36(4):424-435.
7. Gregorevic P, Chamberlain JS. Gene therapy for muscular dystrophy:a review of promising progress. Expert Opin Biol Ther 2003;3(5):803-814.
8. Skuk D, Goulet M, Roy B, Tremblay JP. Myoblast transplantation in whole muscle of nonhuman primates. J Neuropathol Exp Neurol 2000;59(3):197-206. (Pubitemid 30143878)
9. Law PK, Goodwin TG, Fang Q, et al. Feasibility, safety, and efficacy of myoblast trans fer therapy on Duchenne muscular dystrophy boys. Cell Transplant 1992;1(2-3): 235-244.
10. Swinyard CA, Deaver GG, Greenspan L. Gradients of functional ability of importance in rehabilitation of patients with progressive muscular and neuromuscular diseases. Arch Phys Med Rehabil 1957;38(9):574-579.
11. Sookhoo S, Mackinnon I, Bushby K, Chinnery PF, Birchall D. MRI for the demonstration of subclinical muscle involvement in muscular dystrophy. Clin Radiol 2007;62(2): 160-165.
12. Wren TA, Bluml S, Tseng-Ong L, Gilsanz V. Three-point technique of fat quantification of muscle tissue as a marker of disease progression in Duchenne muscular dystrophy: preliminary study. AJR Am J Roentgenol 2008;190(1):W8-W12.
13. Stern LM, Caudrey DJ, Perrett LV, Boldt DW. Progression of muscular dystrophy assessed by computed tomography. Dev Med Child Neurol 1984;26(5):569-573. (Pubitemid 14002371)
14. Schreiber A, Smith WL, Ionasescu V, et al. Magnetic resonance imaging of children with Duchenne muscular dystrophy. Pediatr Radiol 1987;17(6):495-497.
15. Liu GC, Jong YJ, Chiang CH, Jaw TS. Duchenne muscular dystrophy:MR grading system with functional correlation. Radiology 1993;186(2):475-480.
16. Marden FA, Connolly AM, Siegel MJ, Rubin DA. Compositional analysis of muscle in boys with Duchenne muscular dystrophy using MR imaging. Skeletal Radiol 2005;34(3):140-148.
17. Huang Y, Majumdar S, Genant HK, et al. Quantitative MR relaxometry study of muscle composition and function in Duchenne muscular dystrophy. J Magn Reson Imaging 1994;4(1):59-64.
18. Phoenix J, Betal D, Roberts N, Helliwell TR, Edwards RH. Objective quantification of muscle and fat in human dystrophic muscle by magnetic resonance image analysis. Muscle Nerve 1996;19(3):302-310.
19. Maillard SM, Jones R, Owens C, et al. Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis. Rheumatology(Oxford) 2004;43(5):603-608.
20. Patten C, Meyer RA, Fleckenstein JL. T2 mapping of muscle. Semin Musculoskelet Radiol 2003;7(4):297-305.
21. Kight AC, Dardzinski BJ, Laor T, Graham TB. Magnetic resonance imaging evaluation of the effects of juvenile rheumatoid arthritis on distal femoral weight-bearing cartilage. Arthritis Rheum 2004;50(3):901-905.
22. Dardzinski BJ, Laor T, Schmithorst VJ, Klosterman L, Graham TB. Mapping T2 relaxation time in the pediatric knee:feasibility with a clinical 1.5-T MR imaging system. Radiology 2002;225(1):233-239.
23. Dardzinski BJ, Mosher TJ, Li S, Van Slyke MA, Smith MB. Spatial variation of T2 in human articular cartilage. Radiology 1997; 205(2):546-550. (Pubitemid 27467340)
24. Mercuri E, Pichiecchio A, Allsop J, Messina S, Pane M, Muntoni F. Muscle MRI in inherited neuromuscular disorders:past, present, and future. J Magn Reson Imaging 2007; 25(2):433-440.
25. Jaramillo D, Laor T. Pediatric musculoskeletal MRI:basic principles to optimize success. Pediatr Radiol 2008;38(4): 379-391.
26. Carlo B, Roberta P, Roberto S, Marina F, Corrado A. Limb-girdle muscular dystrophies type 2A and 2B:clinical and radiological aspects. Basic Appl Myol 2006;16(1): 17-25.
27. Kliegman R, Nelson WE. Nelson textbook of pediatrics. Philadelphia, Pa :Saunders, 2007.
28. Prior BM, Foley JM, Jayaraman RC, Meyer RA. Pixel T2 distribution in functional magnetic resonance images of muscle. J Appl Physiol 1999;87(6):2107-2114.
29. Sjøgaard G, Saltin B. Extra- and intracellular water spaces in muscles of man at rest and with dynamic exercise. Am J Physiol 1982;243(3):R271-R280.
30. Fullerton GD, Cameron IL, Hunter K, Fullerton HJ. Proton magnetic resonance relaxation behavior of whole muscle with fatty inclusions. Radiology 1985;155(3): 727-730. (Pubitemid 15044778)
31. Zatz M, Rapaport D, Vainzof M, et al. Serum creatine-kinase(CK) and pyruvate-kinase (PK) activities in Duchenne(DMD) as compared with Becker(BMD) muscular dystrophy. J Neurol Sci 1991;102(2):190-196.
32. Malm C, Nyberg P, Engstrom M, et al. Immunological changes in human skeletal muscle and blood after eccentric exercise and multiple biopsies. J Physiol 2000; 529(pt 1):243-262.
33. Davies KE. Challenges in Duchenne muscular dystrophy. Neuromuscul Disord 1997; 7(8):482-486.
34. Costa DN, Pedrosa I, McKenzie C, Reeder SB, Rofsky NM. Body MRI using IDEAL. AJR Am J Roentgenol 2008;190(4):1076-1084.
35. Ababneh Z, Beloeil H, Berde CB, Gambarota G, Maier SE, Mulkern RV. Biexponential parameterization of diffusion and T2 relaxation decay curves in a rat muscle edema model: decay curve components and water compartments. Magn Reson Med 2005;54(3): 524-531.
36. Straub V, Donahue KM, Allamand V, Davisson RL, Kim YR, Campbell KP. Contrast agent-enhanced magnetic resonance imaging of skeletal muscle damage in animal models of muscular dystrophy. Magn Reson Med 2000; 44(4):655-659.
37. Schmidt S, Vieweger A, Obst M, et al. Dysferlin-deficient muscular dystrophy: gadofluorine M suitability at MR imaging in a mouse model. Radiology 2009;250(1): 87-94.
38. Ploutz-Snyder LL, Nyren S, Cooper TG, Potchen EJ, Meyer RA. Different effects of exercise and edema on T2 relaxation in skeletal muscle. Magn Reson Med 1997; 37(5):676-682. (Pubitemid 27187807)
39. Goodpaster BH, Thaete FL, Kelley DE. Composition of skeletal muscle evaluated with computed tomography. Ann N Y Acad Sci 2000;904:18-24.
40. Goodpaster BH, Stenger VA, Boada F, et al. Skeletal muscle lipid concentration quantified by magnetic resonance imaging. Am J Clin Nutr 2004;79(5):748-754. (Pubitemid 41103874)